| Subgroup; outcome | Underwent anticoagulation therapy | Did not undergo anticoagulation therapy | HR (95% CI)† | ||
|---|---|---|---|---|---|
| Events, no. | Event rate (95% CI)* | Events, no. | Event rate (95% CI)* | ||
| All patients (n = 10 745) | |||||
| All stroke and death | 1492 | 73.7 (70.0-77.7) | 1605 | 112.6 (107.0-118.3) | 0.70 (0.62-0.72) |
| Ischemic stroke | 237 | 11.8 (10.3-13.5) | 263 | 18.0 (15.8-20.4) | 0.69 (0.58-0.82) |
| Hemorrhagic stroke | 56 | 2.8 (2.1-3.7) | 22 | 1.5 (1.0-2.4) | 1.92 (1.17-3.16) |
| All stroke | 279 | 14.0 (12.3-15.8) | 276 | 19.0 (16.8-21.5) | 0.77 (0.65-0.91) |
| Death | 1338 | 63.8 (60.4-67.4) | 1478 | 102.0 (96.8-107.4) | 0.67 (0.62-0.72) |
| Primary prevention cohort (n = 9568) | |||||
| All stroke and death | 1265 | 70.6 (66.7-74.7) | 1361 | 103.7 (98.2-109.5) | 0.70 (0.65-0.76) |
| Ischemic stroke | 171 | 9.7 (8.3-11.4) | 216 | 15.9 (13.8-18.3) | 0.62 (0.51-0.76) |
| Hemorrhagic stroke | 41 | 2.3 (1.7-3.3) | 19 | 1.4 (0.9-2.3) | 1.71 (0.98-2.96) |
| All stroke | 203 | 11.7 (10.1-13.5) | 227 | 16.9 (14.7-19.3) | 0.71 (0.58-0.85) |
| Death | 1149 | 61.9 (58.3-65.7) | 1248 | 94.2 (89.0-99.7) | 0.68 (0.63-0.74) |
| Secondary prevention (n = 1177) | |||||
| All stroke and death | 227 | 103.9 (90.7-120.1) | 244 | 190.7 (167.2-217.8) | 0.55 (0.46-0.66) |
| Ischemic stroke | 66 | 31.0 (23.9-41.5) | 47 | 37.1 (27.0-50.9) | 0.89 (0.61-1.30) |
| Hemorrhagic stroke | 15 | 6.4 (3.6-13.2) | 3 | 2.2 (0.42-8.9) | 2.96 (0.86-10.25) |
| All stroke | 76 | 35.5 (27.9-46.4) | 49 | 38.6 (28.4-52.7) | 0.97 (0.67-1.39) |
| Death | 189 | 81.5 (70.3-95.7) | 230 | 168.2 (146.9-192.8) | 0.49 (0.40-0.59) |
Note: CI = confidence interval, HR = hazard ratio.
*Adjusted event rate per 1000 person-years.
†Adjusted for sex and CHADS2 (congestive heart failure, hypertension, age ≥ 75 yr, diabetes mellitus and prior stroke or transient ischemic attack) score.